Further GCLP Chemoproteomics contract secured

Proteome Sciences PLC

15 September 2026

 

15 September 2026

 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation

Proteome Sciences plc

(“Proteome Sciences” or the “Company”)

Further GCLP Chemoproteomics contract secured

As initially announced in June this year, Proteome Sciences plc (AIM:PRM) is pleased to now confirm that the Company has secured the expected significant clinical contract for its chemoproteomics platform.  This project has been developed to comply with Good Clinical Laboratory Practice (“GCLP”) accreditation and will be undertaken at our laboratories in Frankfurt, Germany. 

This will be the 3rd contract connected with the same protein for both phase 1 and phase 2 clinical trials that are on-going globally.  Samples are expected to start to be shipped later this year.   The Company envisages that the majority of the work should be completed in 2027.

Richard Dennis, Chief Commercial Officer commented:-

“As reported previously, we continue to see demand from major biopharma clients in the US and Europe for GCLP grade protein assays that require the precision of sophisticated mass spectrometry-based techniques to provide the necessary data to demonstrate the effectiveness of drugs used in clinical trials today.  We anticipate increased requirement for this approach as more complex drugs are taken into clinical trials and future biomanufacturing”.

Proteome Sciences plc
Christopher Pearce, Executive Chairman	Tel: [phone]
Richard Dennis, Chief Commercial Officer
SP Angel Corporate Finance LLP (Nominated Adviser & Broker)

David Hignell/Matthew Johnson (Corporate Finance) Vadim Alexandre (Corporate Broking)

Tel: [phone]

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, with analysis using a range of depletion strategies in combination with TMTcalibrator™ providing access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift  reveals the selectivity that drugs have to binding one or more proteins in the sample proteome.  Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

Further information on the Company can be found on its website at: https://www.proteomics.com/

The Company's LEI is 213800Q62ICXANKU2986.

 

END